The American Food and Drug Administration (FDA) approved the use of the anti-angiogenic inhibitor bevacizumab for the treatment of metastatic human epidermal growth factor receptor 2 (HER2)-negative breast cancer in 2008. This evidence concerns the gene ERBB2 and breast carcinoma.